Spots Global Cancer Trial Database for mammaprint
Every month we try and update this database with for mammaprint cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score | NCT01617954 | Hormone Recepto... | MammaPrint | 18 Years - 90 Years | Agendia | |
The Symphony Triple A Study: Using Symphony in Treatment Decisions Concerning Adjuvant Systemic Therapy | NCT02209857 | Breastcancer Invasive Breast... | 18 Years - | Diakonessenhuis, Utrecht | ||
PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate | NCT03900637 | Breast Cancer | Leuprorelin ace... Letrozole MammaPrint | 19 Years - | Seoul National University Hospital | |
PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe) | NCT02269813 | Breast Cancer | MammaPrint BluePrint TargetPrint | 18 Years - | West German Study Group | |
The Symphony Triple A Study: Using Symphony in Treatment Decisions Concerning Adjuvant Systemic Therapy | NCT02209857 | Breastcancer Invasive Breast... | 18 Years - | Diakonessenhuis, Utrecht | ||
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score | NCT01617954 | Hormone Recepto... | MammaPrint | 18 Years - 90 Years | Agendia | |
Validation of 70-gene MammaPrint Profile in Japanese Population | NCT00904566 | Breast Cancer | 29 Years - 70 Years | Agendia | ||
PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe) | NCT02269813 | Breast Cancer | MammaPrint BluePrint TargetPrint | 18 Years - | West German Study Group |